BEN FENBY APPOINTED CHIEF DEVELOPMENT OFFICER
Dr Ben Fenby joins Thirty Group as Chief Development Officer, effective Jan 6, 2020, from an oncology biotech where he was responsible for the late stage portfolio development and strategy. Prior to this Ben worked at AstraZeneca for ten years in a range of senior scientific and commercial leadership roles, spanning medical affairs, global marketing and strategy and R&D. Most recently Ben was responsible for cross-functional programme leadership of several multi-billion-dollar registration and phase IIIb life-cycle management assets in cardiovascular and respiratory medicine.
Ben studied biochemistry at the University of Oxford and obtained his PhD in transcriptional regulation of key development signalling pathways at Edinburgh University medical school.
30 TECHNOLOGY is developing and defining new models of care to treat many serious medical conditions by enhancing the body’s healing and defence mechanisms.
30 TECHNOLOGY Therapeutic Nitric Oxide